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Relationship between Tumor Size and Survival among
Patients with Resection of Multiple Synchronous
Lung Cancers
Tawee Tanvetyanon, MD,*† Lary Robinson, MD,* K. Eric Sommers, MD,* Eric Haura, MD,*
Jongphil Kim, PhD,*‡ Soner Altiok, MD, PhD,*§ and Gerold Bepler, MD, PhD*
Background: Multiple synchronous non-small cell lung cancers
(NSCLCs) without extrathoracic metastasis are relatively uncom-
mon. Some patients are treated as metastatic disease by chemother-
apy alone; others are treated as multiple primary cancers by surgery.
For those undergoing surgery, limited information exists on the
relationship between tumor size and survival.
Methods: We retrospectively reviewed medical records of patients
with resection of at least two synchronous NSCLC located in 2
lobes during 1997–2008. Those with only satellite nodules in single
lobe were excluded. Cox proportional hazard model was used to
examine the prognostic significance of tumor size in the context of
other clinical parameters including tumor stage, nodal stage, age,
gender, laterality, histology, and pneumonectomy.
Results: There were 116 patients: 57 patients had cancers distrib-
uted in one lung and 59 in both lung. Overall, 186 thoracotomies
were performed, with a 90-day mortality rate of 2.6%. The median
overall survival was 65.1 months (95% confidence interval [CI]:
49.2–83.7). The median size of the largest tumor and the median
sum of tumor sizes were 3.0 and 4.5 cm, respectively. Both were a
significant predictor of survival: hazard ratios per centimeter in-
crease where 1.17 (95% CI: 1.06–1.30, p  0.003) and 1.15 (95%
CI: 1.05–1.26, p  0.003), respectively. Multivariable regression
analysis identified tumor size and lung function as independent
survival predictors.
Conclusion: Among patients with resected multiple synchronous
NSCLC, tumor size is an independent predictor of survival. The size
of the largest tumor performs slightly better than the sum of tumor
sizes in the survival prediction; however, both are much better than
the American Joint Committee on Cancer stage for this purpose.
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The treatment decision in lung cancer is difficult whenseveral suspicious nodules are present in multiple lobes of
lung and all seem individually resectable. Assuming that
these nodules are all non-small cell lung cancers (NSCLCs),
treatment can perhaps be tailored by tumor stage.1 In the
absence of distant metastases, surgery may be advocated if
these lesions represent multiple early-stage lung cancers, also
known as multiple primary lung cancers (MPLCs). However,
if these are multiple metastatic deposits, surgery is unlikely to
have a favorable impact on survival. Unfortunately, it is not
always possible to know the true stage preoperatively or,
more importantly, to reliably predict the survival outcome
after surgery.
A few publications provide insight into the prognosis
and management of this condition. In 1975, Martini and
Melamed2 proposed the criteria for the diagnosis of MPLC.
These pathologic criteria exploit histologic features, nodal
involvement, and the disease-free interval of tumors to aid
clinicians in differentiating MPLC from a metastatic disease
(Table 1). Based on these criteria, the histologic difference
among the cancers holds the key to classification in that those
with discordant histologies are presumed to be MPLC, not
metastatic disease, thus having a more favorable prognosis.
However, it is not always possible to accurately obtain
histologic information from all cancers preoperatively. An-
other relevant publication is the proposed seventh edition
American Joint Committee on Cancer (AJCC) staging sys-
tem3 which classifies cancers of similar histology in multiple
ipsilateral lobes as T4 (stage IIIB) and those with bilateral
distribution as M1a (stage IV). This suggests that cancers
distributed in one lung confer a better prognosis than those in
both lungs; however, this classification schema disregards
tumor size, a potentially important factor.
To date, little is known about the prognostic signifi-
cance of tumor size among patients with multiple synchro-
nous lung cancers. Generally, tumor size is an important
prognostic factor for early-stage lung cancer.4,5 However, its
significance progressively diminishes among patients with
advanced disease, when the risk of death from distant metas-
tasis increases greatly. In addition, for patients undergoing
several surgical procedures, the prognostic importance of
tumor size may be obscured by tumor location and surgical
procedure. For instance, patients with tumors in both lung
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require bilateral resections that may necessitate suboptimal
resections to preserve lung function, thus impairing survival.
Those who require pneumonectomy, regardless of small tu-
mor size, may face an increased risk of operative complica-
tions, thus adversely impacting survival.6 Because tumor size
is more readily known to clinicians than nodal status or
histology, this information may be useful when deciding
whether to recommend a curative resection. In this article, we
investigate the prognostic significance of tumor size on sur-
vival among patients who underwent surgery for multiple
synchronous lung cancers at our institution.
PATIENTS AND METHODS
After approval by the institutional review board,
records of patients with NSCLC who underwent resection
during July 1997–2008 were reviewed. Inclusion criteria
were resection of at least two physically distinct cancers
located in at least two separate lobes of the lung. These
cancers must be synchronous, defined as being detected by
computerized tomography (CT) scan within 2 years from the
date of first cancer resection. Excluded patients were those
with gross residual disease, benign lesions, carcinomas in
situ, carcinoid tumors, or recurrent cancer.
Treatment
Preoperative staging included CT scan, positron emis-
sion tomography (PET) scan (starting in 2000), and medias-
tinoscopy. All patients underwent mediastinal evaluation
which includes PET scan, mediastinoscopy, or lymphadenec-
tomy. Patients with multistation or bulky mediastinal lymph-
adenopathy or distant metastasis did not undergo surgery. If
patients had compromised lung capacity, biopsies of suspi-
cious lung lesions were obtained to avoid an unnecessary
thoracotomy and help design an operative plan that would
enable all appropriate resections. Neoadjuvant chemotherapy
was offered to selected patients with large tumors or those
with small, single-station mediastinal lymphadenopathy.
Staged thoracotomies were used in all but one patient. Ex-
ternal-beam radiation was routinely offered to those with
positive surgical margins.
Data Collection
Tumor size was based on the maximal unidimensional
diameter measured from pathologic specimens. For patients
with satellite nodules in same lobe, the measurement was
based on the largest tumor in that lobe. Staging was based on
the AJCC seventh Edition.3 Stage assignment began by
grouping lesions into similar histologic categories. Each
group received one-stage assignment. For those with multi-
ple-stage assignment (i.e., having cancers of multiple histol-
ogies), the most advanced stage was used for analysis. Ade-
nocarcinomas, regardless of bronchioloalveolar carcinoma
features, were grouped into one histologic category. Patients
were also classified into three groups: unilateral group in
whom tumors were distributed in 2 lobes of the ipsilateral
lung, bilateral group in whom tumors were in both lungs, and
combined group in whom tumors were in both lungs with at
least two lobes involved in one lung. Pulmonary function test
results were taken from the best report, using the Global
Initiative for Chronic Obstructive Lung disease criteria of
forced expiratory volume at 1 second (FEV-1) 80% of
predicted value to define good lung function.7
Statistical Consideration
Overall and progression-free survivals were calculated
from the date of the first thoracotomy to progression or death,
confirmed by the National Social Security Death index.
Progression was defined as a recurrence in the surgical bed,
distant metastasis, or new primary cancer. The rate of surgical
complications and duration of hospitalizations were calcu-
lated based on thoracotomy episodes. Operative mortality
was defined as death within 90 days after thoracotomy. The
follow-up rule was passive and patients were censored before
June 1, 2009. Survival estimate was by the method of Kaplan-
Meier. Log-rank test was used to examine the difference in
the survival estimates between groups. Cox proportional
hazard models were used to examine the risk of death
associated with prognostic parameters. In the multivariable
models, variables with p  0.20 in the univariable analysis
were examined, using a significant level to stay of 0.10 and a
backward selection procedure. All analyses were performed
on SAS, version 9.1.3. All p values were two tailed and
significance level was set at 0.05.
RESULTS
Patient, Surgery, and Tumor Characteristics
Of 2582 patients who underwent resection of lung
cancer during our observation period, 116 patients (4.5%)
were found to meet review criteria (Table 2). Most patients
were asymptomatic and with good lung function. There were
four patients (two in ipsilateral group and two in bilateral
group) who had a history of prior lung cancer. A total of 186
open thoracotomies were performed for 116 patients: 48
patients underwent one thoracotomy; 66 underwent two tho-
racotomies; and two underwent three thoracotomies. The
TABLE 1. Criteria for Diagnosis of Multiple Primary Lung
Cancer
Metachronous tumors
A. Histology different
B. Histology the same, if:
1. Free interval between cancers at least 2 yr or
2. Origin from carcinoma in situ or
3. Second cancer in different lobe or lung, but:
a. No carcinoma in lymphatics common to both
b. No extrapulmonary metastases at time of diagnosis
Synchronous tumors
A. Tumor physically distinct and separate
B. Histology:
1. Different
2. Same, but in different segment, lobe, or lung, if:
a. Origin from carcinoma in situ
b. No carcinoma in lymphatics common to both
c. No extrapulmonary metastases at time of diagnosis
Adapted from J Thorac Cardiovasc Surg. 1975;70:606–612.
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median interval between the first and the last resection was 49
days. In all, there were 244 diseased lobes: 116 lobes in the
unilateral group, 100 lobes in the bilateral group, and 28 lobes
in the combined group. Adjuvant chemotherapy was admin-
istered in 12 patients (10%), adjuvant radiation in 17 patients
(15%), and neoadjuvant chemotherapy in 12 patients (10%).
Pathologic examination demonstrated that 31% of pa-
tients had cancers of multiple histologic types (Table 3).
There was only one patient with pure bronchioloalveolar
carcinoma in all lesions. One patient had a mixed adenocar-
cinoma and small cell carcinoma in one of his lesions. Based
on the Martini and Melamed’s criteria, 12 patients did not
have MPLC: 11 had a carcinoma in lymphatics common to
both cancers and one had an extrathoracic (adrenal) metasta-
sis. There were 22 node-positive patients. Of these, 11 pa-
tients did not meet the MPLC criteria, eight patients had only
N1 disease, and three patients had N2 disease but the histol-
ogy in the node was different from the other separate primary
cancers.
Surgical Outcomes and Survivals
For both the first thoracotomy (n 116) and the second
or third thoracotomy (n  68) respectively, the median
lengths of hospital stay were 5 days (range 2–41 and 2–69
days). At the first thoracotomy, complications occurred in 20
patients (17%); at the second or third thoracotomies compli-
cations occurred in 14 patients (21%). In the order of episodic
frequency, complications were atrial fibrillation (ten), infec-
tion (ten), persistent air leak requiring redo thoracotomy
(five), prolonged respiratory failure (four), symptomatic sub-
cutaneous emphysema (three), bleeding requiring redo thora-
cotomy (two), severe metabolic acidosis (one), and chylotho-
rax (one). Overall, death within 90 days from surgery
occurred in five of the 186 thoracotomies (2.6%). Causes of
death were respiratory failure (three patients), bleeding (one
patient), and aspergillosis (one patient). Among those who
survived beyond 90 days from surgery, one became ventilator
dependent and two became oxygen dependent. To date,
progressive disease has occurred in 36 patients: 27 with
recurrent or metastatic disease and nine with new primary
lung cancers. Deaths have occurred in 57 patients. The
median progression-free survival was 47.6 months (95%
confidence interval: 33.1–58.1). The median overall survival
was 65.1 months (95% confidence interval: 49.2–83.7).
Impact of Tumor Size on Survival
We investigated the effect of tumor size on survival
using two strategies: by the largest tumor size and by the sum
of tumor sizes. By the largest tumor size, Kaplan-Meier
survival curve indicated a progressive deterioration in sur-
vival as tumor size increased (Figure 1). Patients with largest
tumor size of 3 cm or less (n  68) had a median overall
survival of 83.4 months, compared with 24.3 months among
those with largest tumor size greater than 7 cm (n  5; p 
0.01 by Log-rank trend test). By the sum of tumor size,
similar finding was observed. Those with the sum of tumor
size of 3 cm or less (n 27) had a median overall survival of
125.7 months, compared with 14.8 months among those with
the sum of tumor sizes greater than 9 cm (n  9; p  0.003
by Log-rank trend test). For progression-free survivals, a
similar finding was also observed: progression-free survival
progressively decreased as tumor size increased (Figure 2).
Multivariable Analyses of Prognostic
Parameters
We examined the effect of tumor size on survival in the
context of other known prognostic factors using Cox propor-
tional hazard model. We first performed univariable analyses
(Table 4). Potentially significant variables were then exam-
TABLE 2. Patient and Disease Characteristics
Characteristics
Total
(n  116)
Patient
Male gender (%) 47 (41)
Median (range) age (yr) 70 (45–86)
FEV-1 80% of predicted value (%)a 37 (41)
Surgery
Undergoing staging PET scan (%) 103 (89)
Undergoing mediastinoscopy (%) 13 (11)
Undergoing 2 thoracotomies (%) 68 (59)
Pneumonectomy (%) 10 (9)
No. of wedge resections or segmentectomies performed
None (%) 25 (22)
1 (%) 91 (78)
Tumor
T
T1 a, b (%) 23 (20)
T2 a, b (%) 33 (28)
T3 (%) 17 (15)
T4 (%) 43 (37)
N
0 (%) 94 (81)
1 (%) 8 (7)
2 (%) 14 ((12)
M
0 (%) 71 (61)
1 a, b (%) 45 (39)
Stage
I A, B (%) 15 (13)
II A, B (%) 11 (9)
III A (%) 39 (34)
III B (%) 6 (5)
IV (%) 45 (39)
Median tumor size (range)
Largest tumor size in cm 3.0 (0.7–15.0)
Sum of the largest tumor sizes in affected lobes in cm 4.5 (1.1–16.0)
Pathology
Presence of multiple histology (%) 36 (31)
Positive margins in 1 lesion (%) 13 (11)
Brochiolo-alveolar carcinoma in 1 lesion (%) 25 (22)
Squamous cell carcinoma in 1 lesion (%) 35 (30)
Vascular invasiona 21 (21)
a Percentage calculated from available data: FEV-1 in 90 patients and vascular
invasion in 104 patients.
FEV-1, forced expiratory volume at 1 second; PET, positron emission tomography.
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FIGURE 1 A, Overall survival classified by the largest tumor size. B, Overall survival classified by the sum of tumor sizes.
FIGURE 2 A, Progression-free survival classified by the largest tumor size. B, Progression -free survival classified by the sum of
tumor sizes.
TABLE 3. Histological Characteristics
Histology
Specimens from Patients
Who Met MPLC
Criteria (%) n  218
Specimens from Patients
Who Did Not Meet
MPLC Criteria
(%) n  24
Specimens from Patients
Who Had Multiple
Types of Histology
(%) n  74
Specimens from Patients
Who Did Not Have
Multiple Types of
Histology (%) n  168
All Specimens
(%) n  242
Adenocarcinoma,
adenocarcinoma with
bronchioloalveolar features,
or adenosquamous
carcinoma
125 (57) 22 (92) 27 (37) 115 (68) 147 (60)
Squamous cell carcinoma 47 (21) 0 (0) 23 (31) 24 (14) 47 (19)
Pure bronchioloalveolar
carcinoma
25 (11) 2 (8) 5 (7) 22 (13) 27 (11)
Large cell or large cell
neuroendocrine
carcinoma
10 (4) 0 (0) 7 (9) 3 (2) 10 (4)
Non-small cell carcinoma,
not specified
16 (7) 0 (0) 12 (16) 4 (3) 16 (6)
MPLC, multiple primary lung cancer.
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TABLE 4. Univariable and Multivariable Analysis of Survival Predictors
Characteristics N HR 95% CI
P
(Univariable)
P
(Multivariable
Model Aa)
P
(Multivariable
Model Ba)
Patient
Gender
Male 47 1.00 Reference 0.05 NS NS
Female 69 0.59 0.35–0.99
Age
per a 5-yr increase 116 1.01 0.84–1.21 0.96
FEV-1
80% 53 1.00 Reference 0.03 0.04 0.01
80% 37 2.03 1.07–3.83
Surgery
Interval between first and final
thoracotomy
90 d 80 1.00 Reference 0.68
90 d 36 0.89 0.50–1.57
Pneumonectomy
No 106 1.00 Reference 0.48
Yes 10 1.36 0.58–3.18
Wedge resection or segmentectomy
0 25 1.00 Reference 0.89
1 91 0.96 0.51–1.79
Tumor
Distribution
Unilateral 57 1.00 Reference
Bilateral 50 0.71 0.40–1.25 0.24
Combined 9 0.89 0.37–2.19 0.81
T
T1 23 1.00 Reference 0.41
T2 33 1.78 0.73–4.35
T3 17 1.99 0.76–5.24
T4 43 2.04 0.88–4.76
N
N0 94 1.00 Reference 0.29
N1 or N2 22 1.42 0.74–2.73
M
M0 71 1.00 Reference 0.28
M1 45 0.74 0.42–1.28
Stage
I 15 1.00 Reference 0.54
II 11 1.59 0.56–4.57
III 45 1.11 0.47–2.59
IV 45 0.85 0.35–2.03
Tumor size (per cm increase)
Largest tumor size 116 1.17 1.06–1.30 0.003 0.01
Sum of tumor sizes 116 1.15 1.05–1.26 0.003 0.01
Pathology
No. of histologies
Multiple 36 1.00 Reference 0.46
Single 80 1.23 0.71–2.14
Positive margins
none 103 1.00 Reference 0.002 NS NS
1 lesion 13 2.81 1.48–5.36
Bronchioloalveolar carcinoma
0 91 1.00 Reference 0.59
1 lesion 25 1.19 0.93–2.22
(Continued)
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ined in two multivariable analyses: Model A, using the
largest tumor size, and Model B, using the sum of tumor
sizes. In the univariable analysis, potential prognostic param-
eters were gender, FEV-1, tumor size, vascular invasion, and
positive margins. However, in the multivariable model A,
only the largest tumor size and FEV-1 remained significant.
In model B, only the sum of tumor sizes and FEV-1 remained
significant. These findings remained unchanged, when pro-
gression-free survival was used as an outcome of interest.
DISCUSSION
In this cohort of patients with resected multiple NSCLC
who had a median overall survival well more than 5 years, we
observed that their tumor sizes, reflected by either the largest
tumor size or the sum of tumor sizes, were highly predictive
of survival. As tumor size increased, survival progressively
worsened. Interestingly, we did not find that the tumor stage
or stage group as proposed by AJCC was a significant
predictor of survival. In addition to the tumor size, FEV-1
was also an independent predictor of survival.
To our knowledge, this is one of the largest studies of
resected synchronous multiple lung cancers, not including
reports that contain patients with satellite nodules in one lobe.
The incidence of surgical morbidity and mortality was low,
although this may be an underestimate due to the retrospec-
tive nature of the study. The 5-year survival of our patients is
within the published wide range of 18 to 76%.8–16 In these
reports, survival seems favorable in the patient subsets of
mostly bronchioloalveolar carcinomas,8–10 multiple cancers
in one lobe,8,11–14 or metachronous cancers.9,13,15 In terms of
prognostic parameters, some reports have documented the
importance of nodal involvement,11–13 pneumonectomy,11,12
highest T stage,14 comorbidity,12 and anatomic distribution.12
However, we found no previous reports focusing on the
significance of tumor size.
Based on our findings, tumor size, not the AJCC stag-
ing, is an independent prognostic factor. Because tumor size
is a readily available information, in contrast to the AJCC
staging which at least requires the knowledge of histology
(whether similar histology or different histology), we believe
that tumor size is more useful than the AJCC staging for
surgical decision making of synchronous multiple lung can-
cers. However, even among patients who were in the tier of
greatest tumor sizes in our series, long-term survival could
still be observed, although less frequently, after a complete
surgical resection. Therefore, it is important to use the infor-
mation on tumor size along with other factors, including
pulmonary reserve, when making a treatment decision. On
the basis of the favorable survival in this cohort and the fact
that there was a strong relationship between tumor size and
survival, we believe that most patients in our series had
early-stage cancers, although they were classified into mostly
stage III or IV by standard AJCC staging.
A number of limitations should be noted with our
report. First, our series contained a small number of patients
with significant nodal metastasis. Therefore, our findings may
not be generalizable to such patients. Patients with gross N2
disease have a much worse prognosis than those with micro-
scopic N2 disease,17 thus diminishing the prognostic signifi-
cance of tumor size. Second, other prognostic parameters,
such as tumor clonality analysis using the pattern of somatic
DNA changes, may be more prognostic of survival than
tumor size.18 Third, because this is a retrospective review and
not a randomized study, it is unknown if other therapeutic
options such as stereotactic body radiation19 and/or systemic
therapy20 would produce a comparable result.
In our practice, surgical candidates with multiple
suspicious nodules undergo resections after a recommen-
dation from multidisciplinary tumor board consensus. Pa-
tients are routinely investigated for possible distant metas-
tasis using PET scan, brain magnetic resonance imaging,
and up-to-date contrast-enhanced chest CT scan. Finally,
our report contains mostly patients who were asymptom-
atic with a good lung function and the results may be
confounded by a selection bias.
In summary, tumor size is an independent prognostic
factor for patients with resected synchronous multiple
NSCLC. Surgery is an effective treatment option for patients
with multiple, synchronous lung cancers. Tumor size, in
TABLE 4. (Continued)
Characteristics N HR 95% CI
P
(Univariable)
P
(Multivariable
Model Aa)
P
(Multivariable
Model Ba)
Squamous cell carcinoma
0 81 1.00 Reference 0.37
1 lesion 35 1.29 0.74–2.24
Poorly differentiated cancer
0 55 1.00 Reference 0.82
1 lesion 61 1.06 0.62–1.80
Vascular invasion
0 83 1.00 Reference 0.06 NS NS
1 lesion 21 1.86 0.97–3.57
a Only variables analyzed in multivariable proportional hazard models are shown; Model A including the largest tumor size and Model
B including the sum of tumor size.
NS, not statistically significant; HR, hazard ratio; FEV-1, forced expiratory volume at 1 second.
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addition to pulmonary reserve, may be helpful when making
a decision whether to offer surgery to such patients.
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